Teladoc pushes Solo deeper into remote monitoring and ambient documentation
Teladoc Health is widening its Solo virtual care platform with two additions aimed at hospitals and health systems: a contactless vital-signs monitoring tool and an ambient AI scribe for clinical documentation. The move places the company squarely in two of the most crowded areas of health IT, where workflow burden and documentation fatigue have become as important to buyers as the underlying technology itself.
The new monitoring feature, SoloVitals, is designed to track heart rate and respiratory rate without physical contact. In practical terms, that matters because it allows care teams to gather physiologic data without attaching additional devices to a patient or disrupting routine observation. The system uses a camera to capture facial skin color and applies an optical technique that measures changes in blood volume by analyzing those color shifts. In virtual nursing and patient observation settings, that approach could reduce the friction that often slows down continuous monitoring programs.
A second tool, SoloScribe, handles documentation. It records and transcribes both in-person and virtual encounters and then generates clinical notes for the clinician. Ambient documentation has become one of the most closely watched uses of generative AI in care delivery because it targets a problem clinicians recognize immediately: the time lost to charting after the patient encounter ends. In a hospital or health-system setting, a working scribe tool can change the rhythm of the visit itself, reducing the need to toggle between conversation and keyboard.
Solo already supports e-consultations, virtual nursing and patient observation. It draws information from EHRs, wall-mounted and mobile cameras, and tablets to build analytics dashboards for care teams. The addition of remote vital-sign monitoring and ambient documentation turns the platform into a more integrated layer of bedside and virtual workflow. Teladoc is also making a strategic argument with the product design: one platform may be easier for health systems to manage than a patchwork of separate point solutions, each with its own procurement path, interface and training burden.
Health systems are under pressure to do more while navigating more vendors, more tools and more technical handoffs. In that environment, consolidation can be an operational advantage even before a product shows clear downstream clinical gains. Fewer disconnected systems can mean less duplicate login fatigue, fewer handoffs between teams and a simpler route to adoption across nursing, physician and administrative workflows.
The timing also reflects Teladoc’s own business strain. The company reported a net loss of $200.3 million in 2025 and lowered its 2026 revenue outlook in July. It now expects revenue of $2.36 billion to $2.45 billion this year, a 5% reduction from prior guidance. Much of that pressure is tied to BetterHelp, its mental health division, which has faced demand and capacity issues. During the second-quarter earnings call, CEO Chuck Divita said demand outstripped BetterHelp’s capacity, even after the division added 2,000 more providers credentialed to accept insurance.
The commercial logic behind the new Solo features is obvious. Health IT buyers are not only evaluating accuracy and interoperability; they are also looking for tools that reduce cognitive load. Ambient AI scribing addresses the documentation burden that can erode clinician bandwidth, while touchless vital-sign capture fits the broader push toward passive monitoring and lower-contact workflows. In a hospital, those two capabilities can sit at the center of very different but equally expensive problems: nursing surveillance and clinician documentation overhead.
The clinical utility will depend on performance in real-world settings. Optical assessment of heart rate and respiratory rate must remain dependable across different skin tones, lighting conditions, camera angles and levels of patient movement. Ambient scribing, meanwhile, has to capture clinical nuance cleanly enough to avoid adding correction work after the visit. If either tool produces inconsistent output, the workflow benefit disappears quickly. Hospitals do not keep technology that creates more review time than it saves.
There is also a broader market signal embedded in the rollout. Digital health vendors continue to move toward packaged, workflow-centered offerings rather than narrow standalone tools. That shift reflects what many buyers already know from experience: point solutions can solve a single problem while creating several new ones. A platform that combines monitoring, observation and documentation is easier to sell, easier to implement and easier to defend in a budget cycle.
Teladoc’s announcement places Solo in a more competitive lane, but it also reveals how the company is trying to reposition its health system business. The immediate target is not only clinical efficiency; it is product stickiness. Hospitals that adopt monitoring, virtual nursing and documentation through one vendor are less likely to fragment those functions across multiple platforms later.
The remaining question is whether the new tools can prove they reduce workload without introducing new technical overhead. Teladoc has made the platform argument. The harder test comes when clinicians decide whether the software genuinely disappears into the background of care delivery or becomes one more screen to manage.